A B S T R A C T An in vitro system for perifusion of rat pancreatic islets has been utilized to define the effects of epinephrine on acetylcholine-induced insulin release over varying concentrations of the two agents. Perifusion of islets with epinephrine before challenge with acetylcholine produced marked enhancement of both phases of cholinergically induced insulin release; enhancement of the first phase being more marked with increase in acetylcholine concentration and the converse being observed with the second phase. Perifusion of islets with epinephrine during stimulation with acetylcholine produced inhibition of insulin release, an effect dependent upon the concentration of epinephrine and of acetylcholine. There was an order of difference in the acetylcholine concentration needed to overcome significant epinephrine-mediated inhibition of the first phase of insulin release (5 X 10' Ag/ml) and that needed to overcome inhibition of the second phase (5 X 10-' g/ ml). Comparison of the effects of various concentrations of epinephrine on glucose-and acetyl-choline-induced insulin release revealed that epinephrine was a less potent inhibitor of the first phase of acetylcholine-induced insulin release than of the first phase of glucose-induced insulin release. These data provide some insight into the potential interactions between cholinergic and adrenergic autonomic systems in modifying insulin release.
INTRODUCTION
The often reciprocal effects mediated through the sympathetic and parasympathetic nervous systems form the basis for much of our understanding regarding the role of the autonomic nervous system in contributing to homeostatic mechanisms in general. Teleologically, this concept should be applicable to metabolic homeostasis (1) . Over the last few decades, data has accumulated to Dr. Burr is an Investigator of the Howard Hughes Medical Institute.
Received for publication 1 October 1975 and in rezised form 26 February 1976. indicate the central mechanisms through which an organism may control its metabolic homeostasis with respect to the external environment (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Similarly, the same or similar central areas can exert control over the internal metabolic milieu (16) (17) (18) (19) (20) (21) (22) . Pathways through which these latter effects could be mediated include direct autonomic nervous system control over tissue metabolism (23) (24) (25) (26) and direct control mediated through autonomic nervous system modification of hormonal release (18-21, 23, 26-31) .
Pertinent to this report are the observations regarding the effect of adrenergic agents in inhibiting insulin release via a-adrenergic receptors; stimulating release, via P-adrenergic receptors (32), or; "priming" B cells for enhanced responsiveness to subsequent glucose challenge (31, 33) and similar data indicating the ability of cholinergic mechanisms to stimulate insulin release (29, (34) (35) (36) (37) (38) . Thus, much is known about the independent effects of these autonomic systems on insulin release. However, little is known about the interelationship between these two systems as they affect insulin release. This concern becomes pertinent in light of present concepts of neural control of metabolic processes outlined above.
In this study an attempt has been made to define the interactions between the parasympathetic and the adrenergic systems in modifying the dynamics of insulin re- lease. An in vitro perifusion system has been used in which biphasic insulin release in response to constant challenge by glucose (38) and(or) acetylcholine (39) has been demonstrated. The following questions were considered. Does (41) . Two sets of 40 islets were utilized in each experiment allowing for simultaneous performance of control and test experiments from the same pool of islets. Islets were perifused utilizing a previously described perifusion apparatus (31, 33, 39, 42) which permits appropriate temperature control (thermostate-pump-water bath), gassing of buffer (with 5% C02, 95% o02) and continuous collection of perifusate in a fraction collector housed in a cold box.
Collected samples were frozen at the end of each experiment for assay of insulin content by a modification of the Hales and Randle double-antibody method (43) .
Islets (40 per chamber) were perifused at buffer flow rates of 2.2-2.4 ml/min in both the prestimulation period of 25 min and the subsequent test or control period of 60 min with Krebs-Ringer bicarbonate containing 0.5 g/100 ml albumin and 50 mg/100 ml glucose to which was added: (a) acetylcholine in concentrations from 5 x 10-a ,ug/ml (0.27 nM) to 10'1 ug/ml (5.4 AM) during the test period, or (b) with epinephrine 0.5 ,g/ml (2.3 AM) plus acetylcholine in varying concentrations during the test period, or (c) epinephrine 0.5 ,ug/ml during the prestimulation period followed by acetylcholine in varying concentrations during the test period, or (d) with epinephrine 0.5 i&g/ml added during both the prestimulation and the test periods, or (e) with no additions, series (d) and (e) representing appropriate controls for series (a), (b), and (c).
A further series of experiments were performed utilizing epinephrine in concentrations of 0.01 ->0.5 ug/ml (0.11-2.3 ,MM) in either the prestimulation buffer and(or) the stimulation buffer in the presence of either 0.01 /,g/ml acetylcholine (54 nM) or 300 mg/100 ml glucose (16.4 mM) as the stimulating agent.
In each experimental series patterns of insulin release were defined by measuring the insulin concentration in all samples of the perifusate over the first 10 min and every fifth sample thereafter. The perifusate was collected in aliquots representing 1-min intervals for the latter 5 min of the prestimulation period, 30-s intervals for the initial 10 min of the stimulating (test or control) period and 1-min intervals for the remainder of this second period. All experiments were performed at least six times. Total amounts of insulin released in each of the two phases were defined by reference to the insulin concentration; time plots either by addition for the acute (first phase, T1) response where all samples were measured, or by calculation (from the area subtended by the insulin release: time curve) for the sec- Insulin Release Dynamics-Cholinergic and Adrenergic Interaction (a)-(c), As in Table I ; (d), 0.02 ,g/ml = 54 nM.
epinephrine present through both the prestimulation and the stimulation periods. ACh ondary response where every fifth sample was measured (second phase, T2). Table I summarizes the insulin responses obtained during acetylocholine stimulation over the concentration range of 5 X 10' ,ug/ml (0.27 nM) to 1 X 10' Ag/ml (5.4 AM) in the absence of epinephrine and when a fixed concentration 0.5 Ag/ml (2.3 AM) was added to the buffer either before or during acetylcholine stimulation. The effect of varying the concentration of epinephrine added to either the prestimulation buffer or the stimulation buffer, or both, on the insulin released in response to acetylcholine or glucose challenge, is summarized in Tables II and III, Tables   TABLE I I nephrine had minimal or no effect upon the second phase Addition of epinephrine during stimulation with acetyl-of acetylcholine-induced insulin release (Fig. 3) . choline ( Fig. 1 , Tables I and II) produced dose-depenThe effect of maintaining epinephrine throughout both dent inhibition of insulin release. Both phases of acetyl-the prestimulation and stimulation periods is indicated choline induced biphasic insulin release were affected--iff Table- II. There was no evidence for any effect on However, the inhibitory effect of 0.5 ,ug/ml (2.3 aM) acetylcholine-induced insulin release under these cirepinephrine on either phase was much less marked with cumstances. higher concentrations of acetylcholine (Fig. 3 ). There
RESULTS
The effect of varying the epinephrine concentration was a twofold difference in the acetylcholine concentra-on the ability of epinephrine to either enhance (when tion needed to overcome significant epinephrine-mediated added to the prestimulation buffer) or inhibit (when inhibition of the first phase of insulin release, achieved added with acetylcholine) acetylcholine-induced insulin at 5 X 10' uAg/ml (2.7 nM) acetylcholine and that con-release, is summarized in Table II . It is apparent that centration of acetylcholine, 1 X 10' /Lg/ml (5.4 nM) while the effect of epinephrine is dose dependent over required to overcome epinephrine-mediated inhibition of the concentration range 0.01-0.5 ,sg/ml (0.11-2.3 uM) the second phase of acetylcholine-induced insulin release. there is very little difference in the effects of 0.1 and As indicated in Fig. 2 and Tables I and II (series c) , 0.5 ,ug/ml of epinephrine on either enhancing or inperifusion of islets with epinephrine before subsequent hibiting acetylcholine-induced insulin release. acetylcholine stimulation enhanced both phases of cho- Table III summarizes the data obtained when variable linergically induced insulin release. This effect was de-concentrations of epinephrine are added either before, pendent upon the concentration of acetylcholine used or during stimulation of islets with 300 mg/100 ml glu- (Table I and Fig. 3 ) and differed for the two phases. cose. The qualitative effects of epinephrine on glucoseThe percentage of enhancement of the first phase of induced insulin release can be seen to be similar to the acetylcholine-induced insulin release attributable to prior effects of epinephrine on acetylcholine-induced insulin exposure to epinephrine tended to increase with incr pase release. With these concentrations of glucose and acetylin the concentration of acetylcholine (Fig. 3) nephrine. Moreover, as illustrated in Fig. 4 , differences in epinephrine responsiveness between acetylcholineand glucose-induced insulin release are observed as the concentration of epinephrine is changed. In particular, epinephrine at all concentrations was a less potent inhibitor of the first phase of insulin release induced by acetylcholine than of the first phase of glucose-induced insulin release. A similar differential effect of epinephrine was observed on the second phase of acetylcholine-and glucose-induced insulin release at the higher epinephrine concentration (0.5 ,g/ml). In contrast to the effect of epinephrine on acetylcholine-induced insulin release, a marked difference in the effectiveness of 0.1 vs. 0.5 Mg/ml epinephrine was demonstrated with glucose-induced insulin release. A similar difference between acetylcholine and glucose-induced insulin release was observed in the dose response to epinephrine when epinephrine was added before stimulation with the insulinogogue. However, under these circumstances the high epinephrine concentration produced greater enhancement of both first and second phase insulin responses to glucose than enhancement of acetylcholine-induced insulin release, whereas, at the lower epinephrine concentration the converse was observed. That is, a fivefold change in epinephrine concentration had little effect on the action of epinephrine on acetylcholine-induced insulin release, but did have a significant effect on glucose-induced insulin release.
Finally, epinephrine added before stimulation of islets with either glucose or acetylcholine, produced a more marked enhancement of the primary than of the secondary insulin release response.
DISCUSSION
In this study, an in vitro system was utilized to assess the interrelationship between epinephrine and acetylcholine (ACh) on the dynamics of insulin release and to compare the effects of epinephrine on substrate (glucose) and cholinergically induced insulin release. The concentrations of ACh used (ranging from 0.27 nM to 5.4 FM) are at, or below, the dissociation constant for acetylcholine (10' M) and thus, are assumed to be within the physiologically significant range. The concentration of glucose utilized (16.4 mm) is approximately half that needed for maximal stimulation in most in vitro systems and the concentration of epinephrine (106 M) is that which produces significant, but not complete, suppression of glucose-induced insulin release in vitro; that is, a concentration which in vitro effectively mimics demonstrable in vivo effects.
The results obtained in this study indicate that epinephrine has variable effects on acetylcholine-induced insulin release, which are dependent on both the concentration of epinephrine utilized, and on the temporal relationship between the exposure to epinephrine and the challenge with acetylcholine, with inhibition occurring when epinephrine is added with the acetylcholine. A cooperative effect between epinephrine and acetylcholine was observed when islets were exposed to epinephrine before acetylcholine challenge. That is, preincubation with epinephrine resulted in enhancement of the insulin response to subsequent acetylcholine challenge. No apparent effect was observed on acetylcholine-induced in-234 I. M. Burr sulin release when islets were continuously exposed to epinephrine before and during acetylcholine challenge. In these above respects, the effects of epinephrine on insulin responses to acetylcholine are qualitatively comparable to its effects on glucose-induced insulin release.
The data provide the basis for a more detailed analysis of this phenomenon. This analysis will consider the following. First, the relative effectiveness of epinephrine in inhibiting either the first of the second phase of acetylcholine-induced insulin release and the effect of variation in ACh and epinephrine (Epi) concentration on this effect. Second, the effect of changes in epinephrine and acetylcholine concentration on the cooperative (priming effect) and the relative effectiveness of such priming on the two phases of acetylcholine-induced insulin release. Third, the relative effectiveness of epinephrine in modifying ACh and glucose-induced insulin release.
The inhibition by epinephrine of the first phase of insulin release induced by acetyicholine could be overcome by a concentration of acetylcholine at least one order of magnitude less than that concentration of acetylcholine necessary to overcome the inhibitory effect of epinephrine on the second phase of acetylcholine-induced insulin release. Further, when the acetylcholine concentration approached the binding constant for ACh (1 AM), the inhibitory effect of a comparable, but higher concentration of epinephrine (2.7 ,M) was abolished. That is, the qualitative and quantitative integrity of the insulin release response to acetycholine can readily be attained in the face of epinephrine by increasing the concentration of acetylcholine within the presumed physiological range. In particular, the acute responsiveness of the insulin release mechanism is maintained (first phase insulin release) at lower ACh concentrations than the later phase in the face of epinephrine inhibition. Thus, the effector mechanism exists for ensuring appropriate acute (first phase) insulin release even in the face of enhanced adrenergic tone.
Preincubation with epinephrine before stimulation with acetylcholine produced enhancement of both phases of ACh-induced insulin release and, apart from the response to the lowest concentration of ACh used, 5 X 10' stg/ml (0.27 nM) produced a greater degree of enhancement of the first, than of the second phase of ACh induced insulin release over a wide range of ACh ACh-induced insulin release similar to that observed when glucose is used as the insulinogogue. Thus, the results of epinephrine priming in vitro indicate that appropriately timed adrenergic stimulation can provide a mechanism for maintaining the integrity of the acute insulin response of the islet to subsequent stimulation, whether by substrate (e.g., food), or by acethycholine (e.g., reflectly induced release). In contrast to the "priming" and "inhibiting" effects of epinephrine on ACh-and glucose-induced insulin release, the addition of epinephrine during both the stimulation and the prestimulation periods, does not influence the insulin response to either ACh or glucose, either quantitatively or qualitatively. While it must be assumed that the apparent net cancellation of priming and inhibitory effects is the result of an accident of experimental design (that is the duration of preincubation and stimulatory periods), the observation did hold true over a range of epinephrine concentrations. Thus, it would appear from this data that for optimal insulin release, that adrenergic tone, acting specifically on B-cell islets, should be maximal during nonsecretory phases (e.g., in pre-or interprandial) periods and minimal during periods of insulin response (e.g., to feeding, whether the response be induced reflexly [ACh] , or by a rise in substrate availability, glucose). An alternative, but not mutually exclusive, explanation would be that rate of decrement in intensity of adrenergic stimulation may be important in producing the priming effect. If the reverse were true, insulin release would be inhibited; if adrenergic "tone " remained unaltered, then the insulin release response would be similar to that of adrenergically denervated islets (that is, less than that obtained with "appropriately" innervated or "primed" islets). The existence of "tonic" adrenergic stimulation to B cells in fasting state is indicated by the effect of chemical sympathectomy which produces elevated fasting insulin levels, despite attenuated insulin release in response to challenge (44) .
Comparison of the effects of epinephrine on ACh-induced insulin release and on glucose-induced insulin release reveals a number of potentially important points. First, epinephrine appears to be a more potent inhibitor of glucose-induced insulin release than of ACh-induced insulin release. This is illustrated by the fact that 0.5 Ag/ml (2.7 uM) epinephrine produces 50% inhibition of the first phase and 24% inhibition of the second phase of glucose-induced insulin release (using 16.4 mM glucose) and only 14% and 13% inhibition respectively of the first and second phases of acetylcholine-induced insulin release (using 0.01 Lg/ml ACh which induces approximately the same quantitative and qualitative insulin release pattern as 16.4 mM glucose). Second, the responses of glucose-induced insulin release to adrenergic "priming" and to adrenergic inhibition are more responsive to changes in epinephrine concentration than are the responses induced by ACh. That is, marked changes in enhancement and inhibition are observed with glucose-induced insulin release over the range 0.1-0.5 ug/ml of epinephrine, whereas, the responses to ACh are little modified over this range. That is, enhancement of first phase insulin release by epinephrine priming with glucose as the insulinogogue is more dependent on a high epinephrine preincubation concentration than is the enhancement of the first phase of AChinduced insulin release. Conversely, the first phase of glucose-induced release is more likely to be inhibited by high epinephrine concentrations. To summarize the above, effective mechanisms exist, whereby appropriately timed adrenergic and cholinergic impulses can modify the quantitative and qualitative patterns of insulin release. Further, they indicate that there is temporally related cooperativity between the two systems; that is, the systems can function other than in a simple antagonist fashion. The studies suggest that optimal biphasic responses, and in particular, optimal acute insulin release would be expected when adrenergic stimulation or "tone" to B cells increases during interprandial periods and decreases with onset of insulin release which, in turn is stimulated by both an increase in effective acetylcholine concentration at B-cell receptor sites (through reflex mechanisms, cephalic [45, 46] and local [47, 48] and increases in substrate (glucose) concentration. The availability of such an autonomic mechanism for producing optimal acute insulin responses assumes importance in the light of data which indicates that the acute insulin response to glucose challenge is a prime determinant of the rate of glucose disappearance under physiological conditions (49) (50) (51) (52) (53) .
Finally, the above studies provide support for the suggestion that the anomalies observed in insulin release in some diabetics (54) (55) (56) could be related to anomalous or absent autonomic modification of B-cell function (31, 42, 57) . The anomalies include: a quantitative reduction in the amount of insulin released in response to glucose challenge (54) in some, but not all, (58) diabetics with retention of apparently normal responsiveness to theophyllin (59) and glucagon (60) , and a "delay" in insulin release in response to glucose challenge (54) (55) (56) 61) . This latter anomaly perhaps representing the in vivo equivalent (61) of a markedly impaired first phase response to the artificial situation of square wave glucose challenge seen in vitro. That is, deficiency in either epinephrine priming and(or) cholinergic stimulation or anomalous temporal initiation of these effects (with loss of cooperatively) would all tend to reduce the amount of insulin released over both phases, and in particular, would produce relatively greater impairment of the first phase response.
